Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

Fintel reports that on November 4, 2025, Needham maintained coverage of Vertex (NasdaqGM:VERX) with a Buy recommendation.

One key figure, however, indicates otherwise as sales for Journavx were at $20 million for the period, coming up $3 million ...

The stock of niche financial software company Vertex ( VERX 4.13%) didn't get a very good start to the trading week at all.

Frustrated by the price of a lifesaving cystic fibrosis treatment sold by Vertex Pharmaceuticals, a group of families is ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.

BMO Capital analyst Daniel Jester lowered the firm’s price target on Vertex (VERX) to $24 from $30 and keeps a Market Perform rating on the ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

Katharine Paljug is a financial writer and editor with over a decade of industry experience. Her writing has covered nearly every aspect of the financial world, from investing in forex to paying for ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without regular ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. David Kindness is a Certified Public ...